Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 2/20 | 0.32 |
| ▸ | CCND1 | P24385 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9898823 | 0.85 | CDK4 (0.36) | KMT2AMAPTNPC1MEN1GAA | |
| SCHEMBL1009767 | 0.85 | CDK4 (0.36) | KMT2AMAPTNPC1MEN1GAA | |
| SCHEMBL6818231 | 0.83 | PARP1 (0.37) | GSK3BPARP1PTPN1KMT2AMAPT | |
| SCHEMBL165110 | 0.82 | PDK2 (0.40) | PARP1PTPN1KMT2AKDM4ERAB9A | |
| SCHEMBL30125362 | 0.82 | PDK2 (0.40) | PARP1PTPN1KMT2AKDM4ERAB9A | |
| SCHEMBL23572603 | 0.82 | PPM1A (0.37) | KMT2AMAPTMEN1GAAALK | |
| SCHEMBL1815597 | 0.82 | KCNH2 (0.36) | GSK3BPARP1PTPN1KMT2AMAPT | |
| SCHEMBL30104206 | 0.82 | PPM1A (0.37) | KMT2AMAPTMEN1GAAALK | |
| SCHEMBL30125565 | 0.82 | MEN1 (0.34) | PARP1PTPN1KMT2AMEN1POLB | |
| SCHEMBL1816046 | 0.82 | TTR (0.34) | PARP1PTPN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9465234-B2 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150301357-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | JOHNSON & JOHNSON VISION CARE (US) | 2015-10-22 | — | — | US | disclosed |
| US-9139552-B2 | Indeno-fused naphthopyrans having ethylenically unsaturated groups | TRANSITIONS OPTICAL, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2494408-B9 | PHOTOCHROMIC MATERIALS | TRANSITIONS OPTICAL INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9097916-B2 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2494408-B1 | PHOTOCHROMIC MATERIALS | TRANSITIONS OPTICAL INC (US) | 2015-04-15 | — | — | EP | disclosed |
| US-20140225049-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8741188-B2 | Ophthalmic devices comprising photochromic materials having extended pi-conjugated systems | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8647538-B2 | Photochromic compounds having at least two photochromic moieties | TRANSITIONS OPTICAL, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8518305-B2 | Photochromic materials | TRANSITIONS OPTICAL, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-7481955-B2 | Photochromic materials comprising metallocenyl groups | TRANSITIONS OPTICAL, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| WO-2008021375-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1872173-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1869140-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | Johnson and Johnson Vision Care, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007140058-A1 | PHOTOCHROMIC MATERIALS COMPRISING METALLOCENYL GROUPS | TRANSITIONS OPTICAL, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070278460-A1 | Photochromic materials comprising metallocenyl groups | TRANSITIONS OPTICAL LIMITED (IE) | 2007-12-06 | — | — | US | disclosed |
| WO-2006110513-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110221-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060228557-A1 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | TRANSITIONS OPTICAL, INC. | 2006-10-12 | — | — | US | disclosed |
| US-20060226402-A1 | Ophthalmic devices comprising photochromic materials having extended PI-conjugated systems | KIM BEON-KYU | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060228557-A1 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | INCENP, PCNA, INTS6 | GSK3B 2878/4885PARP1 166/4885PTPN1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.